Barclays PLC Vera Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 85,395 shares of VERA stock, worth $3.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,395

Previous 85,395 -0.0%

Holding current value

$3.58 Million

Previous $3.77 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$34.09 - $46.71 $1.41 Million - $1.93 Million	41,394 Added 94.08%	85,395 $3.77 Million
Q2 2024 Aug 14, 2024	BUY	$33.72 - $48.82 $14,600 - $21,139	433 Added 0.99%	44,001 $1.59 Million
Q1 2024 May 15, 2024	SELL	$14.91 - $49.14 $1.05 Million - $3.45 Million	-70,179 Reduced 61.7%	43,568 $1.88 Million
Q4 2023 Feb 15, 2024	BUY	$9.29 - $16.0 $390,588 - $672,704	42,044 Added 58.64%	113,747 $1.75 Million
Q3 2023 Nov 07, 2023	BUY	$13.71 - $19.64 $890,711 - $1.28 Million	64,968 Added 964.63%	71,703 $983,000
Q2 2023 Aug 03, 2023	SELL	$6.11 - $17.83 $25,888 - $75,545	-4,237 Reduced 38.62%	6,735 $107,000
Q1 2023 May 04, 2023	SELL	$5.41 - $18.3 $12,480 - $42,218	-2,307 Reduced 17.37%	10,972 $85,000
Q4 2022 Feb 13, 2023	BUY	$15.74 - $22.19 $51,217 - $72,206	3,254 Added 32.46%	13,279 $256,000
Q3 2022 Nov 03, 2022	BUY	$13.27 - $22.31 $123,795 - $208,129	9,329 Added 1340.37%	10,025 $214,000
Q2 2022 Aug 12, 2022	SELL	$12.82 - $23.4 $19,563 - $35,708	-1,526 Reduced 68.68%	696 $9,000
Q1 2022 May 16, 2022	BUY	$17.8 - $28.06 $39,551 - $62,349	2,222 New	2,222 $53,000

Others Institutions Holding VERA

# of Institutions

184

Shares Held

55.1M

Call Options Held

134K

Put Options Held

156K

View Full List

About Vera Therapeutics, Inc.

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.13B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

More about VERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account